ArticleCancer discovery2018
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 140 citations in OpenAlex.
- Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.Clinical epigenetics · 2023Trial
- A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer.Molecular medicine reports · 2026Article
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- Comprehensive overview of AI methodologies in nano-drug delivery Optimization and Design.NPJ precision oncology · 2026Review
- Discovery of ZJC-11 as a Novel Selective CDK7 Inhibitor for Treating Triple-Negative Breast Cancer by Inducing Cell Senescence.Journal of medicinal chemistry · 2026Article
- ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.Science advances · 2026Article
- Drug-tolerant persister cells: the deadly survivors in hematological malignancies.Frontiers in pharmacology · 2026Review
- Targeting Drug-Tolerant Persister Cancer Cells: Can Nanomaterial-Based Strategies Be Helpful for Anti-DTP Therapies?Pharmaceutics · 2025Review
- Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review.Journal of Zhejiang University. Science. B · 2025Review
- Deciphering functional landscape and clinical implications of enhancer RNAs in lung adenocarcinoma.Scientific reports · 2025Article
- Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment.Molecular cancer · 2025Review
- Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer.Molecular oncology · 2025Article
- Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.Military Medical Research · 2025Review
- Cancer 3D Models: Essential Tools for Understanding and Overcoming Drug Resistance.Oncology research · 2025Review
- YY1 downregulation underlies therapeutic response to molecular targeted agents.Cell death & disease · 2024Article
- Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.NPJ precision oncology · 2024Article
- Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.Nature reviews. Cancer · 2024Review
- Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer.Cell death & disease · 2024Article
- Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2024Review
- Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.Nature communications · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
33 authors at 2 institutions in 2 countries.
Maria RusanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kapsok LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Yvonne LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Camilla L ChristensenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Brian J AbrahamWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Nicholas KwiatkowskiWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Kevin A BuczkowskiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Bruno BockornyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ting ChenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Shuai LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kevin RheeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Haikuo ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Wankun ChenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hideki TeraiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tiffany TavaresDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Alan L LeggettDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tianxia LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Yichen WangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tinghu ZhangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tae-Jung KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sook-Hee HongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Neermala Poudel-NeupaneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Michael SilkesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tenny MudiantoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Li TanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Takeshi ShimamuraMolecular Pharmacology and Therapeutics, Oncology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois.
Matthew MeyersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Adam J BassDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Hideo WatanabeDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Nathanael S GrayDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Richard A YoungWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Kwok-Kin WongLaura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Peter S HammermanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. peter.hammerman@novartis.com.
Aarhus University · DKShanghai Medical College of Fudan University · CN
Funding
StructureP01CA154303 · NCI · DANA-FARBER CANCER INST · PI MEYERSON, MATTHEW L. · 2012 to 2021
$17.8MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MTargeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung CancerU01CA213333 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GRAY, NATHANAEL SCHIANDER, WONG, KWOK KIN · 2017 to 2021
$3.3MIn vivo analysis of EGFR mutant driven lung cancers responses to radiation therapR01CA122794 · NCI · DANA-FARBER CANCER INST · PI WONG, KWOK KIN · 2006 to 2015
$2.8MIn vivo murine models of metastasis for therapeutic testingR01CA163896 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHARPLESS, NORMAN E, WONG, KWOK KIN · 2012 to 2016
$2.0MTherapeutic targeting of Fibroblast Growth Factor Receptors in Squamous CancersR01CA196932 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2015 to 2019
$1.9MDevelopment and Application of Selective Covalent Cdk7 InhibitorsR01CA179483 · NCI · DANA-FARBER CANCER INST · PI GRAY, NATHANAEL SCHIANDER, MITSIADES, CONSTANTINE S. · 2014 to 2016
$1.5MGenomic Discovery and Targeted Therapeutics in Squamous Cell Lung CancerK08CA163677 · NCI · DANA-FARBER CANCER INST · PI HAMMERMAN, PETER S · 2012 to 2016
$783kInvestigation and targeting of the transcriptional and epigenetic landscape of Small Cell Lung CancerK99CA201618 · NCI · DANA-FARBER CANCER INST · PI CHRISTENSEN, CAMILLA L · 2016 to 2017
$257kNCI NIH HHS K08 CA163677NCI NIH HHS K99 CA201618NCI NIH HHS P01 CA154303NCI NIH HHS R01 CA122794NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA163896NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA179483NCI NIH HHS R01 CA196932NCI NIH HHS U01 CA213333
Abstract
Acquired drug resistance is a major factor limiting the effectiveness of targeted cancer therapies. Targeting tumors with kinase inhibitors induces complex adaptive programs that promote the persistence of a fraction of the original cell population, facilitating the eventual outgrowth of inhibitor-resistant tumor clones. We show that the addition of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and
Indexed as
Cell Line, TumorHumansNeoplasmsSignal Transduction
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.